PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural...
Primary Outcome Measures: Incidence of chest wall tract metastasis 6 months from randomisation [ Time Frame: 6 months ] [ Designated as safety issue: No ] Secondary Outcome Measures: Time from...
View ArticleA Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced...
Primary Outcome Measures: Maximum Tolerated Dose (MTD) [ Time Frame: Up to 1 year or longer if indicated. ] [ Designated as safety issue: Yes ] Number of participants with adverse events [ Time Frame:...
View ArticleRegister With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy...
Detailed Description: To register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC. In this surgical intervention, the...
View ArticlePhase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell...
Primary Objective: To assess clinical response rates of mithramycin administered as 6hour intravenous infusionsin patients with malignancies involving lungs, esophagus, pleura, or mediastinum....
View ArticleSafety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma...
Primary Outcome Measures: Adverse events and serious adverse events occurence [ Time Frame: One month following treatment initiation ] [ Designated as safety issue: Yes ] Secondary Outcome Measures:...
View ArticleMithramycin for Lung, Esophagus, and Other Chest Cancers
Detailed Description: Increasing evidence indicates that activation of stem cell gene expression is a common mechanism by which environmental carcinogens mediate initiation and progression of thoracic...
View ArticleIntracavitary Cisplatin-Fibrin Localized Chemotherapy After...
Primary Outcome Measures: number of participants with adverse events [ Time Frame: during 4 weeks after surgery with local cisplatin-fibrin application ] [ Designated as safety issue: Yes ] local...
View ArticleA Study of LY3023414 in Participants With Advanced Cancer
Primary Outcome Measures: Recommended Phase 2 dose [ Time Frame: Baseline to disease progression or participant discontinuation (estimated 9 weeks) ] [ Designated as safety issue: Yes ] Secondary...
View ArticleThe Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
Primary Outcome Measures: To determine the objective response [ Time Frame: Weeks 24 ] [ Designated as safety issue: No ] The objective response is defined as a confirmed complete response (CR), or...
View ArticleCRS-207 Cancer Vaccine in Combination With Chemotherapy as Front-line...
Primary Outcome Measures: Number of subjects reporting adverse events [ Time Frame: From first study dose through duration of study (up to 30 weeks or longer) ] [ Designated as safety issue: Yes ]...
View ArticleRe-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural...
Primary Outcome Measures: Safety [ Time Frame: until 35 days after transfer of re-directed T cells ] [ Designated as safety issue: Yes ] Incidence and severity of treatment-related laboratory...
View ArticlePhase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell...
Primary Objective: To assess clinical response rates of mithramycin administered as 6hour intravenous infusionsin patients with malignancies involving lungs, esophagus, pleura, or mediastinum....
View ArticleSafety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma...
Primary Outcome Measures: Adverse events and serious adverse events occurence [ Time Frame: One month following treatment initiation ] [ Designated as safety issue: Yes ] Secondary Outcome Measures:...
View ArticleMithramycin for Lung, Esophagus, and Other Chest Cancers
Detailed Description: Increasing evidence indicates that activation of stem cell gene expression is a common mechanism by which environmental carcinogens mediate initiation and progression of thoracic...
View ArticleIntracavitary Cisplatin-Fibrin Localized Chemotherapy After...
Primary Outcome Measures: number of participants with adverse events [ Time Frame: during 4 weeks after surgery with local cisplatin-fibrin application ] [ Designated as safety issue: Yes ] local...
View ArticleA Study of LY3023414 in Participants With Advanced Cancer
Primary Outcome Measures: Recommended Phase 2 dose [ Time Frame: Baseline to disease progression or participant discontinuation (estimated 9 weeks) ] [ Designated as safety issue: Yes ] Secondary...
View ArticleThe Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
Primary Outcome Measures: To determine the objective response [ Time Frame: Weeks 24 ] [ Designated as safety issue: No ] The objective response is defined as a confirmed complete response (CR), or...
View ArticleCRS-207 Cancer Vaccine in Combination With Chemotherapy as Front-line...
Primary Outcome Measures: Number of subjects reporting adverse events [ Time Frame: From first study dose through duration of study (up to 30 weeks or longer) ] [ Designated as safety issue: Yes ]...
View ArticleEarly Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos
Primary Outcome Measures: Development of Model to Predict Workers at highest risk of lung cancer/mesothelioma [ Time Frame: 3 years ] [ Designated as safety issue: No ] Eligibility Criteria Study...
View ArticleIntrapleural Administration of HSV1716 to Treat Patients With Malignant...
Primary Outcome Measures: Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma. [ Time Frame: Dose...
View Article
